PSA-tests bij mannen ouder dan 74 jaar: zwart-wit of toch een grijs gebied?

Sebastiaan Remmers; Renée Hogenhout; ERSPC Rotterdam Study Group; Monique J. Roobol

doi:10.1007/s13629-020-00317-4

PSA-tests bij mannen ouder dan 74 jaar: zwart-wit of toch een grijs gebied?

Translated title of the contribution: PSA based screening in men over the age of 74 years: a black-and-white issue or a grey area?

Sebastiaan Remmers, Renée Hogenhout, ERSPC Rotterdam Study Group, Monique J. Roobol^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › Academic › peer-review

161 Downloads (Pure)

Abstract

Men >70–74 years of age are excluded from PSA-based screening for prostate cancer because of overdiagnosis. In this study we will determine if we should apply PSA-based screening in elderly in terms of life expectancy and quality of life. Men aged between 70–74 years randomly assigned in the screening group of the Dutch ERSPC and not diagnosed with prostate cancer at time of screening were included. Incidence and mortality were described. In the end 3,040 men were included. During a follow up of 24 years, 202 (7%) were diagnosed with prostate cancer of which 52 (26%) developed metastasis and 26% died of prostate cancer. PSA at time of screening predicted prostate cancer specific mortality (PCSM). Concluded was that men > 74 years of age should not be refrained from screening given the risk of metastasis and the mortality rate. Health assessment and counseling together with PSA testing and further risk stratification are the key to a valid screening strategy.

Translated title of the contribution	PSA based screening in men over the age of 74 years: a black-and-white issue or a grey area?
Original language	Dutch
Pages (from-to)	22-32
Number of pages	11
Journal	Tijdschrift voor Urologie
Volume	11
Issue number	2-3
DOIs	https://doi.org/10.1007/s13629-020-00317-4
Publication status	Published - Mar 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13629-020-00317-4Licence: CC BY

PSA-tests bij mannen ouder dan 74 jaar. zwart-wit of toch een grijs gebiedFinal published version, 524 KBLicence: CC BY

Cite this

@article{52a8bde11273418bba9d74b019c9bf19,

title = "PSA-tests bij mannen ouder dan 74 jaar: zwart-wit of toch een grijs gebied?",

abstract = "Men >70–74 years of age are excluded from PSA-based screening for prostate cancer because of overdiagnosis. In this study we will determine if we should apply PSA-based screening in elderly in terms of life expectancy and quality of life. Men aged between 70–74 years randomly assigned in the screening group of the Dutch ERSPC and not diagnosed with prostate cancer at time of screening were included. Incidence and mortality were described. In the end 3,040 men were included. During a follow up of 24 years, 202 (7%) were diagnosed with prostate cancer of which 52 (26%) developed metastasis and 26% died of prostate cancer. PSA at time of screening predicted prostate cancer specific mortality (PCSM). Concluded was that men > 74 years of age should not be refrained from screening given the risk of metastasis and the mortality rate. Health assessment and counseling together with PSA testing and further risk stratification are the key to a valid screening strategy.",

author = "Sebastiaan Remmers and Ren{\'e}e Hogenhout and {ERSPC Rotterdam Study Group} and Roobol, {Monique J.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = mar,

doi = "10.1007/s13629-020-00317-4",

language = "Dutch",

volume = "11",

pages = "22--32",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science+Business Media",

number = "2-3",

}

TY - JOUR

T1 - PSA-tests bij mannen ouder dan 74 jaar

T2 - zwart-wit of toch een grijs gebied?

AU - Remmers, Sebastiaan

AU - Hogenhout, Renée

AU - ERSPC Rotterdam Study Group

AU - Roobol, Monique J.

PY - 2021/3

Y1 - 2021/3

N2 - Men >70–74 years of age are excluded from PSA-based screening for prostate cancer because of overdiagnosis. In this study we will determine if we should apply PSA-based screening in elderly in terms of life expectancy and quality of life. Men aged between 70–74 years randomly assigned in the screening group of the Dutch ERSPC and not diagnosed with prostate cancer at time of screening were included. Incidence and mortality were described. In the end 3,040 men were included. During a follow up of 24 years, 202 (7%) were diagnosed with prostate cancer of which 52 (26%) developed metastasis and 26% died of prostate cancer. PSA at time of screening predicted prostate cancer specific mortality (PCSM). Concluded was that men > 74 years of age should not be refrained from screening given the risk of metastasis and the mortality rate. Health assessment and counseling together with PSA testing and further risk stratification are the key to a valid screening strategy.

AB - Men >70–74 years of age are excluded from PSA-based screening for prostate cancer because of overdiagnosis. In this study we will determine if we should apply PSA-based screening in elderly in terms of life expectancy and quality of life. Men aged between 70–74 years randomly assigned in the screening group of the Dutch ERSPC and not diagnosed with prostate cancer at time of screening were included. Incidence and mortality were described. In the end 3,040 men were included. During a follow up of 24 years, 202 (7%) were diagnosed with prostate cancer of which 52 (26%) developed metastasis and 26% died of prostate cancer. PSA at time of screening predicted prostate cancer specific mortality (PCSM). Concluded was that men > 74 years of age should not be refrained from screening given the risk of metastasis and the mortality rate. Health assessment and counseling together with PSA testing and further risk stratification are the key to a valid screening strategy.

UR - http://www.scopus.com/inward/record.url?scp=85102427364&partnerID=8YFLogxK

U2 - 10.1007/s13629-020-00317-4

DO - 10.1007/s13629-020-00317-4

M3 - Article

AN - SCOPUS:85102427364

SN - 2211-3037

VL - 11

SP - 22

EP - 32

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 2-3

ER -